Market Place
Sourcing Support
Bayer To Present New Prostate Cancer Data At ESMO 2024
05 Sep 2024 //
BUSINESSWIRE
Bayer recalls one lot of cancer drug Vitrakvi due to contamination
18 Nov 2023 //
BUSINESSWIRE
Latest Vitrakvi Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy
02 Jun 2023 //
BUSINESSWIRE
Tissue-agnostic drug development: FDA oncology center offers draft guidance
18 Oct 2022 //
ENDPTS
Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact
06 Jul 2022 //
BIOSPACE
Vitrakvi Support Consistently Meaningful Clinical Profile in TRK Fusion Cancer
16 Sep 2021 //
BUSINESSWIRE
Precision oncology treatment Larotrectinib submitted for marketing in China
25 May 2021 //
PRESS RELEASE
FDA approves Foundation Medicine`s diagnostic for Vitrakvi
26 Oct 2020 //
FIERCEBIOTECH
FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors
23 Oct 2020 //
PRESS RELEASE
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers
18 Sep 2020 //
PHARMATIMES
Data Supporting Profile of Vitrakvi (larotrectinib) for TRK Fusion Cancer
16 Sep 2020 //
BUSINESSWIRE
Larotrectinib Data Further Demonstrate Strong Efficacy in TRK+ Tumors
03 Jun 2020 //
ONCLIVE
The Efficacy of Vitrakvi® (larotrectinib) Further Demonstrated High Response
29 May 2020 //
BUSINESSWIRE
NICE issues final guidance on NHS use of Bayer`s Vitrakvi
27 May 2020 //
PHARMA TIMES
Bayer seeks Japanese mkt approval for larotrectinib to treat TRK fusion cancer
25 May 2020 //
PHARMABIZ
Bayer and ArcherDX Announce Global Collaboration to Develop (NGS)
14 May 2020 //
BUSINESSWIRE
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20
11 May 2020 //
BUSINESSWIRE
Bayer and OrigiMed reached a partnership to develop a (NGS)
29 Apr 2020 //
PRNASIA
Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research
23 Apr 2020 //
BUSINESSWIRE
Bayer`s Vitrakvi becomes first tumour-agnostic therapy approved by NICE
21 Apr 2020 //
PHARMAFILE
Bayer to showcase new data including research in immuno-oncology
21 Jan 2020 //
BUSINESS WIRE
German drug assessment body not convinced by Bayer`s cancer drug Vitrakvi
17 Jan 2020 //
REUTERS
Bayer Announces Updated Analysis for Vitrakvi®Demonstrating High Response Rate
30 Sep 2019 //
PR NEWSWIRE
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
24 Sep 2019 //
PMLIVE
Inside drugmakers` strategy to boost cancer medicines with `Lazarus effect`
06 Sep 2019 //
REUTERS
Roche’s tumour-agnostic drug approved by FDA, priced under competitor drug
19 Aug 2019 //
IN-PHARMATECHNOLOGIST
Roche cancer drug the 3rd approved for pan-tumor use
16 Aug 2019 //
BIOPHARMADIVE
Bayer gets EU CHMP nod for precision oncology treatment larotrectinib
02 Aug 2019 //
BIOSPECTRUMASIA
EMA committee recommends mkt approval Bayer`s larotrectinib for tumor-agnostic
29 Jul 2019 //
PHARMABIZ
EMA panel recommends approving Bayer`s cancer drug Vitrakvi
26 Jul 2019 //
REUTERS
England to fast-track tumour agnostic drugs like Vitrakvi if the price is right
22 Jun 2019 //
PM LIVE
Roche fields first approval for Rozlytrek
19 Jun 2019 //
ENDPTS
Roche wins Japan approval for personalized cancer drug Rozlytrek
18 Jun 2019 //
REUTERS
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
New data on Vitrakvi in TRK fusion cancer patients with brain metastases
04 Jun 2019 //
PR NEWSWIRE
15 new cancer drugs debuted in 2018—along with one big leap in drug spending
31 May 2019 //
FIERCE PHARMA
Bayer taps a second partner to develop Vitrakvi`s companion diagnostic
30 May 2019 //
BIOCENTURY
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib)
11 Apr 2019 //
PR NEWSWIRE
Bayer posts early clinical data on follow-up to Loxo’s Vitrakvi
01 Apr 2019 //
FIERCE BIOTECH
Bayer to commercialize TRK inhibitor as Roche creates competition
22 Feb 2019 //
IN-PHARMATECHNOLOGIST
Bayer antes up on Vitrakvi just as Roche rival wins fast review
19 Feb 2019 //
FIERCE PHARMA
As Lilly deal closes, Bayer secures full rights to Loxo`s Vitrakvi
16 Feb 2019 //
BIOPHARMA DIVE
Bayer obtains full rights to Vitrakvi® (larotrectinib)& BAY 2731954 (LOXO-195)
15 Feb 2019 //
PR NEWSWIRE
2018 Drug Approvals: A Closer Look
05 Feb 2019 //
SCIENCE MAG BLOG
JPM recap: Must-reads of the week, from FDA to IPO to M&A
12 Jan 2019 //
FIERCE PHARMA
JP Morgan 2019 – Lilly fans the M&A flames with Loxo Oncology deal
09 Jan 2019 //
EVALUATE
#JPM19 starts with Eli Lilly’s $8B buyout of Loxo Oncology — so who’s next?
07 Jan 2019 //
ENDPTS
FDA plans to create a new office to leverage cutting-edge science
05 Jan 2019 //
STAT NEWS
Top 9 Really Cool Life Science Discoveries of the Year
10 Dec 2018 //
BIOSPACE
Roche launches new TRK assay, as Bayer, Loxo get FDA nod for pan-cancer drug
28 Nov 2018 //
FIERCE BIOTECH
Loxo And Bayer`s Amazing Drug Has An Expensive Price
27 Nov 2018 //
FORBES
FDA approves drug for cancers with a certain genetic profile
26 Nov 2018 //
FDA
Roche takes on Loxo, Bayer in gene-defined cancer class
22 Oct 2018 //
REUTERS
Roche takes on Loxo, Bayer in gene-defined cancer class
22 Oct 2018 //
REUTERS
Loxo`s targeted therapy holds up to Roche challenge
20 Oct 2018 //
BIOPHARMA DIVE
Loxo`s targeted therapy holds up to Roche challenge
20 Oct 2018 //
BIOPHARMA DIVE
Another Precision Step for Roche as Ignyta Drug Heads to Regulators
25 Sep 2018 //
XCONOMY
Regulators Detail Challenges in Defining Orphan Conditions in EU
13 Sep 2018 //
RAPS
